Bristol-Myers Squibb News & Latest Bristol-Myers Squibb Headlines

A Simple Strategy to Boost Your Returns

1:35PM 10/18/2011

Pfizer, Bristol-Myers Squibb, Verizon, McDonald's, Merck, Investing Basics, Chevron

Options: It's a word that makes you shiver with fear or salivate at opportunity. In fact, there's one options strategy that's almost certain to add some extra money to your portfolio over time, without adding lots of risk. It's the technique known as writing covered calls, and it's perfect for times like this.

The Dark Cloud Over Growing Antidepressant Prescriptions

4:00PM 8/10/2011

By Melly Alazraki

Health Care, Bristol-Myers Squibb, Eli Lilly, Astrazeneca, Consumer Ally

They call it the Great "Recession," but there's no question that these are depressing times. And doctors are writing scripts for antidepressants at an alarming rate -- especially given that many of these doctors aren't psychiatrists. What are the effects on patients who haven't been properly screened?

Three Favorite Stocks of Wealthy Investors

7:45AM 3/24/2011

By BloggingStocks

Technology, Investing, Health Care, Apple, Bristol-Myers Squibb, Stocks in the News

According to a recent survey, wealthy U.S. investors are the most optimistic than they've been in months. And of those looking to invest more in the stock market, they have several clear ideas on where they'd like to place their bets.

The 10 Biggest-Selling Drugs That Are About to Lose Their Patent

8:00AM 2/27/2011

By Melly Alazraki

Company News, Investing, Health Care, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Merck, Eli Lilly, Astrazeneca

The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.

Pfizer Joins Other Pharmas in Giving a Cautious Outlook

3:41PM 2/01/2011

By Melly Alazraki

Company News, Health Care, Earnings, Pfizer, Bristol-Myers Squibb, Novartis, Eli Lilly, Astrazeneca

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

12:30PM 1/28/2011

By Melly Alazraki

Company News, Columns, Health Care, Genzyme Corporation , Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Novartis, Eli Lilly, Astrazeneca

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

As Diabetes Explodes, Big Pharma Is Gearing Up

6:00PM 1/27/2011

By Melly Alazraki

Investing, Health Care, Bristol-Myers Squibb, Sanofi Aventis, Merck, GlaxoSmithKline, Eli Lilly, Astrazeneca

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver -- and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

AstraZeneca's Brilinta Fails to Win FDA Approval

8:08AM 12/17/2010

By Melly Alazraki

Company News, Health Care, Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Astrazeneca, Stocks in the News

The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study.

FDA Is Set Decide the Fate of AstraZeneca's Heart Drug Brilinta

9:35AM 12/15/2010

By Melly Alazraki

Company News, Health Care, Bristol-Myers Squibb, Sanofi Aventis, Eli Lilly, Astrazeneca, Stocks in the News

More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.

Inside Wall Street: The Growing Interest in Achillion's Hepatitis Drugs

7:30AM 11/01/2010

By Gene Marcial

Company News, Columns, Investing, Health Care, Bristol-Myers Squibb, Stock Picks, Merck

At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention of some players in Big Pharma.